The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

Abstract Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many
cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against …

Recent research in drug discovery dealing with many faces difficulties, including
development of new drugs during disease outbreak and drug resistance due to rapidly …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive
acute myeloid leukemia (AML) remains a challenge despite the development of novel FLT3 …

FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute
myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib …

This dataset contains ligand conformations and docking scores for 1.4 billion molecules
docked against 6 structural targets from SARS-CoV2, representing 5 unique proteins: MPro …

Simple Summary Despite the recent approval of some FLT3 inhibitors by drug regulatory
agencies, treatment guidelines for FLT3-mutated AML still require allogeneic transplantation …

Abstract Purpose of Review Acute myeloid leukemia (AML) in children remains a
challenging disease to cure with suboptimal outcomes particularly when compared to the …